Allon, TURNS Expand Collaboration for Phase II Schizophrenia Trial

Allon Therapeutics announced it, in collaboration with TURNS (Treatment Units for Research on Neurocognition and Schizophrenia) and with support from the National Association for Research in Schizophrenia and Affective Disorders, will add an imaging-biomarker component to the current Phase II efficacy trial evaluating AL-108 as a treatment for schizophrenia-related cognitive impairment.

Three different imaging techniques will be used to investigate whether AL-108 treatment results in a change in the brain structures affected by schizophrenia, Allon said.

The TURNS-Allon study has received institutional review board approval to begin patient enrollment for the Phase II efficacy trial in schizophrenia-related cognitive impairment, the company added.

The company said it expects to being dosing in the multicenter, double blind, placebo-controlled study shortly.